These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

623 related articles for article (PubMed ID: 11854853)

  • 1. Three Rs potential in the development and quality control of immunobiologicals.
    Halder M
    ALTEX; 2001; 18 Suppl 1():13-47. PubMed ID: 11854853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A 4R concept for the safety testing of immunobiologicals.
    Cussler K
    Dev Biol Stand; 1999; 101():121-6. PubMed ID: 10566784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Three Rs potential in the development and quality control of pharmaceuticals.
    Hartung T
    ALTEX; 2001; 18 Suppl 1():3-13. PubMed ID: 11854852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extraneous agents testing for substrates of avian origin and viral vaccines for poultry: current provisions and proposals for future approaches.
    Jungbäck C; Motitschke A
    Biologicals; 2010 May; 38(3):362-5. PubMed ID: 20335053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Calibration of the Ph. Eur. Biological Reference Preparation (BRP) for tetanus vaccine (adsorbed) batch 3.
    Tierney R; Hockley J; Rigsby P; Terao E; Daas A; Buchheit KH; Sesardic D
    Pharmeur Bio Sci Notes; 2011 Jun; 2011(1):1-26. PubMed ID: 21619853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Replacement, reduction and refinement alternatives to animal use in vaccine potency measurement.
    Hendriksen CF
    Expert Rev Vaccines; 2009 Mar; 8(3):313-22. PubMed ID: 19249973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Towards eliminating the use of animals for regulatory required vaccine quality control.
    Hendriksen CF
    ALTEX; 2006; 23(3):187-90. PubMed ID: 17086348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. European Pharmacopoeia (EP), USDA and MAFF standards--will they ever be harmonised under the VICH umbrella?
    Castle P
    Dev Biol (Basel); 2005; 121():227-34. PubMed ID: 15962485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Statistical evaluation of numbers of animals to be used in vaccine potency testing: a practical approach.
    Akkermans AM; Hendriksen CF
    Dev Biol Stand; 1999; 101():255-60. PubMed ID: 10566799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Collaborative study for the establishment of a European Pharmacopoeia Biological Reference Preparation for Clostridia antiserum for serological potency testing of veterinary clostridial vaccines.
    Lucken R; Daas A; Behr-Gross ME
    Dev Biol (Basel); 2002; 111():171-80. PubMed ID: 12678238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alternatives to animal experimentation in basic research.
    Gruber FP; Hartung T
    ALTEX; 2004; 21 Suppl 1():3-31. PubMed ID: 15586255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A short history of the use of animals in vaccine development and quality control.
    Hendriksen CF
    Dev Biol Stand; 1996; 86():3-10. PubMed ID: 8785959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Collaborative study for the standardisation of the histamine sensitizing test in mice and the CHO cell-based assay for the residual toxicity testing of acellular pertussis vaccines.
    Xing D; Maes A; Behr-Gross ME; Costanzo A; Daas A; Buchheit KH
    Pharmeur Bio Sci Notes; 2010 Apr; 2010(1):51-63. PubMed ID: 20223190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alternative methods to safety studies in experimental animals: role in the risk assessment of chemicals under the new European Chemicals Legislation (REACH).
    Lilienblum W; Dekant W; Foth H; Gebel T; Hengstler JG; Kahl R; Kramer PJ; Schweinfurth H; Wollin KM
    Arch Toxicol; 2008 Apr; 82(4):211-36. PubMed ID: 18322675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [100 years of erysipelas prophylaxis: significance and reduction of animal experiments].
    Cussler K; Balks E
    ALTEX; 2001; 18(1):29-33. PubMed ID: 11248847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quality assurance of C. perfringens epsilon toxoid vaccines--ELISA versus mouse neutralisation test.
    Rosskopf-Streicher U; Volkers P; Noeske K; Werner E
    ALTEX; 2004; 21 Suppl 3():65-9. PubMed ID: 15057410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Collaborative study for the establishment of erysipelas ELISA coating antigen. European Biological Reference Preparation batch no. 1.
    Cussler K; Rosskopf-Streicher U; Volkers P; Milne C
    Pharmeuropa Spec Issue Biol; 2001 Aug; 2001(1):75-88. PubMed ID: 11705102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serological assays as alternatives to the Ph Eur challenge test for batch release of tetanus vaccines for human use.
    Winsnes R; Hendriksen C; Sesardic D; Akkermans A; Daas A
    Dev Biol Stand; 1999; 101():277-88. PubMed ID: 10566802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.